万泰生物：重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请获得受理

Core Viewpoint - Wanta Biotechnology (603392.SH) has received acceptance for its clinical trial application for the "Recombinant Trivalent Rotavirus Subunit Vaccine (E. coli)" from the National Medical Products Administration, marking a significant step in the company's vaccine development process [1] Group 1 - The acceptance of the clinical trial application is a crucial advancement in the company's innovative vaccine research and development [1] - This development signifies a key progress in the company's recombinant protein vaccine research strategy based on its proprietary E. coli technology platform [1] - Successful future commercialization of this product could enhance the company's product portfolio and further improve its market competitiveness [1]